Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Identifieur interne : 002E90 ( PascalFrancis/Corpus ); précédent : 002E89; suivant : 002E91Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Auteurs : M. Marre ; J. Shaw ; M. Br Ndle ; W. M. W. Bebakar ; N. A. Kamaruddin ; J. Strand ; M. Zdravkovic ; T. D. Le Thi ; S. ColagiuriSource :
- Diabetic medicine [ 0742-3071 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Liraglutide, Dose journalière, Homme, Rosiglitazone, Peptide GLP1, Analogue, Diabète de type 2, Amélioration, Glycémie, Poids corporel, Surveillance, Etude comparative, Placebo, Plomb, Peptidases, Agoniste, Dérivé de la thiazolidinedione, Endocrinologie, Maladie métabolique, Hypoglycémiant, Etat nutritionnel, Récepteur GLP-1, Incrétine.
English descriptors
- KwdEn :
- Agonist, Analog, Body weight, Comparative study, Daily dose, Endocrinology, Glucagon like peptide 1, Glycemia, Human, Hypoglycemic agent, Improvement, Incretin, Lead, Liraglutide, Metabolic diseases, Nutritional status, Peptidases, Placebo, Rosiglitazone, Surveillance, Thiazolidinedione derivatives, Type 2 diabetes.
Abstract
Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± so), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA1c) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono: combination therapies (30: 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P< 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (<11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 09-0162156 INIST |
|---|---|
| ET : | Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) |
| AU : | MARRE (M.); SHAW (J.); BRÄNDLE (M.); BEBAKAR (W. M. W.); KAMARUDDIN (N. A.); STRAND (J.); ZDRAVKOVIC (M.); LE THI (T. D.); COLAGIURI (S.) |
| AF : | Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard/Paris/France (1 aut.); International Diabetes Institute/Melbourne/Australie (2 aut.); Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen/Suisse (3 aut.); Department of Medicine, Hospital Universiti Sains/Kelantan/Malaisie (4 aut.); Departmentof Medicine, National University of Malaysia (UKM)/Kuala Lumpur/Malaisie (5 aut.); Oulun Diakonissalaitos/Oulu/Finlande (6 aut.); NovoNordisk A/S/Bagsvaerd/Danemark (7 aut., 8 aut.); Insitute of Obesity, Nutrition and Exercise, University of Sydney/Australie (9 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Diabetic medicine; ISSN 0742-3071; Coden DIMEEV; Royaume-Uni; Da. 2009; Vol. 26; No. 3; Pp. 268-278; Bibl. 22 ref. |
| LA : | Anglais |
| EA : | Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± so), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA1c) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono: combination therapies (30: 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P< 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (<11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile. |
| CC : | 002A16E; 002A28; 002B21E01A |
| FD : | Liraglutide; Dose journalière; Homme; Rosiglitazone; Peptide GLP1; Analogue; Diabète de type 2; Amélioration; Glycémie; Poids corporel; Surveillance; Etude comparative; Placebo; Plomb; Peptidases; Agoniste; Dérivé de la thiazolidinedione; Endocrinologie; Maladie métabolique; Hypoglycémiant; Etat nutritionnel; Récepteur GLP-1; Incrétine |
| FG : | Hydrolases; Enzyme; Hormone gastrointestinale; Biométrie corporelle; Endocrinopathie; Métal lourd; Trouble de la nutrition |
| ED : | Liraglutide; Daily dose; Human; Rosiglitazone; Glucagon like peptide 1; Analog; Type 2 diabetes; Improvement; Glycemia; Body weight; Surveillance; Comparative study; Placebo; Lead; Peptidases; Agonist; Thiazolidinedione derivatives; Endocrinology; Metabolic diseases; Hypoglycemic agent; Nutritional status; Incretin |
| EG : | Hydrolases; Enzyme; Gastrointestinal hormone; Corporal biometry; Endocrinopathy; Heavy metal; Nutrition disorder |
| SD : | Liraglutida; Dosis diaria; Hombre; Rosiglitazona; Péptido GLP1; Análogo; Diabetes de tipo 2; Mejora; Glucemia; Peso corporal; Vigilancia; Estudio comparativo; Placebo; Plomo; Peptidases; Agonista; Tiazolidinediona derivado; Endocrinología; Metabolismo patología; Hipoglicemiante; Estado nutricional; Incretina |
| LO : | INIST-20274.354000187360670110 |
| ID : | 09-0162156 |
Links to Exploration step
Pascal:09-0162156Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)</title><author><name sortKey="Marre, M" sort="Marre, M" uniqKey="Marre M" first="M." last="Marre">M. Marre</name><affiliation><inist:fA14 i1="01"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shaw, J" sort="Shaw, J" uniqKey="Shaw J" first="J." last="Shaw">J. Shaw</name><affiliation><inist:fA14 i1="02"><s1>International Diabetes Institute</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Br Ndle, M" sort="Br Ndle, M" uniqKey="Br Ndle M" first="M." last="Br Ndle">M. Br Ndle</name><affiliation><inist:fA14 i1="03"><s1>Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen</s1><s3>CHE</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bebakar, W M W" sort="Bebakar, W M W" uniqKey="Bebakar W" first="W. M. W." last="Bebakar">W. M. W. Bebakar</name><affiliation><inist:fA14 i1="04"><s1>Department of Medicine, Hospital Universiti Sains</s1><s2>Kelantan</s2><s3>MYS</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kamaruddin, N A" sort="Kamaruddin, N A" uniqKey="Kamaruddin N" first="N. A." last="Kamaruddin">N. A. Kamaruddin</name><affiliation><inist:fA14 i1="05"><s1>Departmentof Medicine, National University of Malaysia (UKM)</s1><s2>Kuala Lumpur</s2><s3>MYS</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Strand, J" sort="Strand, J" uniqKey="Strand J" first="J." last="Strand">J. Strand</name><affiliation><inist:fA14 i1="06"><s1>Oulun Diakonissalaitos</s1><s2>Oulu</s2><s3>FIN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zdravkovic, M" sort="Zdravkovic, M" uniqKey="Zdravkovic M" first="M." last="Zdravkovic">M. Zdravkovic</name><affiliation><inist:fA14 i1="07"><s1>NovoNordisk A/S</s1><s2>Bagsvaerd</s2><s3>DNK</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Le Thi, T D" sort="Le Thi, T D" uniqKey="Le Thi T" first="T. D." last="Le Thi">T. D. Le Thi</name><affiliation><inist:fA14 i1="07"><s1>NovoNordisk A/S</s1><s2>Bagsvaerd</s2><s3>DNK</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Colagiuri, S" sort="Colagiuri, S" uniqKey="Colagiuri S" first="S." last="Colagiuri">S. Colagiuri</name><affiliation><inist:fA14 i1="08"><s1>Insitute of Obesity, Nutrition and Exercise, University of Sydney</s1><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0162156</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0162156 INIST</idno><idno type="RBID">Pascal:09-0162156</idno><idno type="wicri:Area/PascalFrancis/Corpus">002E90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)</title><author><name sortKey="Marre, M" sort="Marre, M" uniqKey="Marre M" first="M." last="Marre">M. Marre</name><affiliation><inist:fA14 i1="01"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shaw, J" sort="Shaw, J" uniqKey="Shaw J" first="J." last="Shaw">J. Shaw</name><affiliation><inist:fA14 i1="02"><s1>International Diabetes Institute</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Br Ndle, M" sort="Br Ndle, M" uniqKey="Br Ndle M" first="M." last="Br Ndle">M. Br Ndle</name><affiliation><inist:fA14 i1="03"><s1>Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen</s1><s3>CHE</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bebakar, W M W" sort="Bebakar, W M W" uniqKey="Bebakar W" first="W. M. W." last="Bebakar">W. M. W. Bebakar</name><affiliation><inist:fA14 i1="04"><s1>Department of Medicine, Hospital Universiti Sains</s1><s2>Kelantan</s2><s3>MYS</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kamaruddin, N A" sort="Kamaruddin, N A" uniqKey="Kamaruddin N" first="N. A." last="Kamaruddin">N. A. Kamaruddin</name><affiliation><inist:fA14 i1="05"><s1>Departmentof Medicine, National University of Malaysia (UKM)</s1><s2>Kuala Lumpur</s2><s3>MYS</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Strand, J" sort="Strand, J" uniqKey="Strand J" first="J." last="Strand">J. Strand</name><affiliation><inist:fA14 i1="06"><s1>Oulun Diakonissalaitos</s1><s2>Oulu</s2><s3>FIN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zdravkovic, M" sort="Zdravkovic, M" uniqKey="Zdravkovic M" first="M." last="Zdravkovic">M. Zdravkovic</name><affiliation><inist:fA14 i1="07"><s1>NovoNordisk A/S</s1><s2>Bagsvaerd</s2><s3>DNK</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Le Thi, T D" sort="Le Thi, T D" uniqKey="Le Thi T" first="T. D." last="Le Thi">T. D. Le Thi</name><affiliation><inist:fA14 i1="07"><s1>NovoNordisk A/S</s1><s2>Bagsvaerd</s2><s3>DNK</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Colagiuri, S" sort="Colagiuri, S" uniqKey="Colagiuri S" first="S." last="Colagiuri">S. Colagiuri</name><affiliation><inist:fA14 i1="08"><s1>Insitute of Obesity, Nutrition and Exercise, University of Sydney</s1><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Diabetic medicine</title><title level="j" type="abbreviated">Diabetic med.</title><idno type="ISSN">0742-3071</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Diabetic medicine</title><title level="j" type="abbreviated">Diabetic med.</title><idno type="ISSN">0742-3071</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Analog</term><term>Body weight</term><term>Comparative study</term><term>Daily dose</term><term>Endocrinology</term><term>Glucagon like peptide 1</term><term>Glycemia</term><term>Human</term><term>Hypoglycemic agent</term><term>Improvement</term><term>Incretin</term><term>Lead</term><term>Liraglutide</term><term>Metabolic diseases</term><term>Nutritional status</term><term>Peptidases</term><term>Placebo</term><term>Rosiglitazone</term><term>Surveillance</term><term>Thiazolidinedione derivatives</term><term>Type 2 diabetes</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Liraglutide</term><term>Dose journalière</term><term>Homme</term><term>Rosiglitazone</term><term>Peptide GLP1</term><term>Analogue</term><term>Diabète de type 2</term><term>Amélioration</term><term>Glycémie</term><term>Poids corporel</term><term>Surveillance</term><term>Etude comparative</term><term>Placebo</term><term>Plomb</term><term>Peptidases</term><term>Agoniste</term><term>Dérivé de la thiazolidinedione</term><term>Endocrinologie</term><term>Maladie métabolique</term><term>Hypoglycémiant</term><term>Etat nutritionnel</term><term>Récepteur GLP-1</term><term>Incrétine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± so), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA<sub>1c</sub>) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono: combination therapies (30: 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA<sub>1c</sub> from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P< 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (<11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0742-3071</s0></fA01><fA02 i1="01"><s0>DIMEEV</s0></fA02><fA03 i2="1"><s0>Diabetic med.</s0></fA03><fA05><s2>26</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)</s1></fA08><fA11 i1="01" i2="1"><s1>MARRE (M.)</s1></fA11><fA11 i1="02" i2="1"><s1>SHAW (J.)</s1></fA11><fA11 i1="03" i2="1"><s1>BRÄNDLE (M.)</s1></fA11><fA11 i1="04" i2="1"><s1>BEBAKAR (W. M. W.)</s1></fA11><fA11 i1="05" i2="1"><s1>KAMARUDDIN (N. A.)</s1></fA11><fA11 i1="06" i2="1"><s1>STRAND (J.)</s1></fA11><fA11 i1="07" i2="1"><s1>ZDRAVKOVIC (M.)</s1></fA11><fA11 i1="08" i2="1"><s1>LE THI (T. D.)</s1></fA11><fA11 i1="09" i2="1"><s1>COLAGIURI (S.)</s1></fA11><fA14 i1="01"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>International Diabetes Institute</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen</s1><s3>CHE</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Medicine, Hospital Universiti Sains</s1><s2>Kelantan</s2><s3>MYS</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Departmentof Medicine, National University of Malaysia (UKM)</s1><s2>Kuala Lumpur</s2><s3>MYS</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Oulun Diakonissalaitos</s1><s2>Oulu</s2><s3>FIN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>NovoNordisk A/S</s1><s2>Bagsvaerd</s2><s3>DNK</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Insitute of Obesity, Nutrition and Exercise, University of Sydney</s1><s3>AUS</s3><sZ>9 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>LEAD-1 SU study group</s1><s3>INC</s3></fA17><fA20><s1>268-278</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20274</s2><s5>354000187360670110</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>22 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0162156</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Diabetic medicine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± so), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA<sub>1c</sub>) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono: combination therapies (30: 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA<sub>1c</sub> from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P< 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (<11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.</s0></fC01><fC02 i1="01" i2="X"><s0>002A16E</s0></fC02><fC02 i1="02" i2="X"><s0>002A28</s0></fC02><fC02 i1="03" i2="X"><s0>002B21E01A</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Liraglutide</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Liraglutide</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Liraglutida</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Dose journalière</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Daily dose</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Dosis diaria</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Human</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Rosiglitazone</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Rosiglitazone</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Rosiglitazona</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Peptide GLP1</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Glucagon like peptide 1</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Péptido GLP1</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Analogue</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Analog</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Análogo</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Diabète de type 2</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Type 2 diabetes</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0><s2>NM</s2><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Amélioration</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Improvement</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Mejora</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Glycémie</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Glycemia</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Glucemia</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Poids corporel</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Body weight</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Peso corporal</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Surveillance</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Surveillance</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Vigilancia</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Etude comparative</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Comparative study</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>17</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Plomb</s0><s2>NC</s2><s2>FX</s2><s5>19</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Lead</s0><s2>NC</s2><s2>FX</s2><s5>19</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Plomo</s0><s2>NC</s2><s2>FX</s2><s5>19</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Peptidases</s0><s2>FE</s2><s5>20</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Peptidases</s0><s2>FE</s2><s5>20</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Peptidases</s0><s2>FE</s2><s5>20</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Agoniste</s0><s5>21</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Agonist</s0><s5>21</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Agonista</s0><s5>21</s5></fC03><fC03 i1="17" i2="X" l="FRE"><s0>Dérivé de la thiazolidinedione</s0><s5>22</s5></fC03><fC03 i1="17" i2="X" l="ENG"><s0>Thiazolidinedione derivatives</s0><s5>22</s5></fC03><fC03 i1="17" i2="X" l="SPA"><s0>Tiazolidinediona derivado</s0><s5>22</s5></fC03><fC03 i1="18" i2="X" l="FRE"><s0>Endocrinologie</s0><s5>23</s5></fC03><fC03 i1="18" i2="X" l="ENG"><s0>Endocrinology</s0><s5>23</s5></fC03><fC03 i1="18" i2="X" l="SPA"><s0>Endocrinología</s0><s5>23</s5></fC03><fC03 i1="19" i2="X" l="FRE"><s0>Maladie métabolique</s0><s5>24</s5></fC03><fC03 i1="19" i2="X" l="ENG"><s0>Metabolic diseases</s0><s5>24</s5></fC03><fC03 i1="19" i2="X" l="SPA"><s0>Metabolismo patología</s0><s5>24</s5></fC03><fC03 i1="20" i2="X" l="FRE"><s0>Hypoglycémiant</s0><s5>25</s5></fC03><fC03 i1="20" i2="X" l="ENG"><s0>Hypoglycemic agent</s0><s5>25</s5></fC03><fC03 i1="20" i2="X" l="SPA"><s0>Hipoglicemiante</s0><s5>25</s5></fC03><fC03 i1="21" i2="X" l="FRE"><s0>Etat nutritionnel</s0><s5>26</s5></fC03><fC03 i1="21" i2="X" l="ENG"><s0>Nutritional status</s0><s5>26</s5></fC03><fC03 i1="21" i2="X" l="SPA"><s0>Estado nutricional</s0><s5>26</s5></fC03><fC03 i1="22" i2="X" l="FRE"><s0>Récepteur GLP-1</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="23" i2="X" l="FRE"><s0>Incrétine</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="23" i2="X" l="ENG"><s0>Incretin</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="23" i2="X" l="SPA"><s0>Incretina</s0><s4>CD</s4><s5>97</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hormone gastrointestinale</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Gastrointestinal hormone</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hormona gastrointestinal</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Biométrie corporelle</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Corporal biometry</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Biometría corporal</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Endocrinopathie</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Endocrinopathy</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Endocrinopatía</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Métal lourd</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Heavy metal</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Metal pesado</s0><s5>40</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Trouble de la nutrition</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Nutrition disorder</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Trastorno nutricíon</s0><s5>41</s5></fC07><fN21><s1>117</s1></fN21></pA></standard><server><NO>PASCAL 09-0162156 INIST</NO><ET>Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)</ET><AU>MARRE (M.); SHAW (J.); BRÄNDLE (M.); BEBAKAR (W. M. W.); KAMARUDDIN (N. A.); STRAND (J.); ZDRAVKOVIC (M.); LE THI (T. D.); COLAGIURI (S.)</AU><AF>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard/Paris/France (1 aut.); International Diabetes Institute/Melbourne/Australie (2 aut.); Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen/Suisse (3 aut.); Department of Medicine, Hospital Universiti Sains/Kelantan/Malaisie (4 aut.); Departmentof Medicine, National University of Malaysia (UKM)/Kuala Lumpur/Malaisie (5 aut.); Oulun Diakonissalaitos/Oulu/Finlande (6 aut.); NovoNordisk A/S/Bagsvaerd/Danemark (7 aut., 8 aut.); Insitute of Obesity, Nutrition and Exercise, University of Sydney/Australie (9 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Diabetic medicine; ISSN 0742-3071; Coden DIMEEV; Royaume-Uni; Da. 2009; Vol. 26; No. 3; Pp. 268-278; Bibl. 22 ref.</SO><LA>Anglais</LA><EA>Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± so), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA<sub>1c</sub>) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono: combination therapies (30: 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA<sub>1c</sub> from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P< 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (<11%), vomiting (< 5%) and diarrhoea (< 8%). Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.</EA><CC>002A16E; 002A28; 002B21E01A</CC><FD>Liraglutide; Dose journalière; Homme; Rosiglitazone; Peptide GLP1; Analogue; Diabète de type 2; Amélioration; Glycémie; Poids corporel; Surveillance; Etude comparative; Placebo; Plomb; Peptidases; Agoniste; Dérivé de la thiazolidinedione; Endocrinologie; Maladie métabolique; Hypoglycémiant; Etat nutritionnel; Récepteur GLP-1; Incrétine</FD><FG>Hydrolases; Enzyme; Hormone gastrointestinale; Biométrie corporelle; Endocrinopathie; Métal lourd; Trouble de la nutrition</FG><ED>Liraglutide; Daily dose; Human; Rosiglitazone; Glucagon like peptide 1; Analog; Type 2 diabetes; Improvement; Glycemia; Body weight; Surveillance; Comparative study; Placebo; Lead; Peptidases; Agonist; Thiazolidinedione derivatives; Endocrinology; Metabolic diseases; Hypoglycemic agent; Nutritional status; Incretin</ED><EG>Hydrolases; Enzyme; Gastrointestinal hormone; Corporal biometry; Endocrinopathy; Heavy metal; Nutrition disorder</EG><SD>Liraglutida; Dosis diaria; Hombre; Rosiglitazona; Péptido GLP1; Análogo; Diabetes de tipo 2; Mejora; Glucemia; Peso corporal; Vigilancia; Estudio comparativo; Placebo; Plomo; Peptidases; Agonista; Tiazolidinediona derivado; Endocrinología; Metabolismo patología; Hipoglicemiante; Estado nutricional; Incretina</SD><LO>INIST-20274.354000187360670110</LO><ID>09-0162156</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002E90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:09-0162156
|texte= Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
}}
| This area was generated with Dilib version V0.6.33. |  |